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2Abstract
Plasma adrenaline mainly originates from adrenaline-containing cells in the 
adrenal medulla, whereas plasma noradrenaline reflects not only the release from 
sympathetic nerves but also the secretion from noradrenaline-containing cells in the
adrenal medulla. The present study was undertaken to examine the mechanisms 
involved in centrally administered epibatidine (a potent agonist of nicotinic 
acethylcholine receptors)-induced elevation of plasma catecholamines with regard to
the brain prostanoid. Intracerebroventricularly (i.c.v.) administered epibatidine (1, 5 
and 10 nmol/animal) effectively elevated plasma noradrenaline and adrenaline. The 
epibatidine (5 nmol/animal, i.c.v.)-induced elevation of both catecholamines was 
attenuated by hexamethonium (an antagonist of nicotinic acethylcholine receptors) (0.9 
and 1.8 µmol/animal, i.c.v.), indomethacin (an inhibitor of cyclooxygenase) (0.6 and 
1.2 µmol/animal, i.c.v.) and (+)-S-145 (an antagonist of prostanoid TP receptors) (0.6 
and 1.3 µmol/animal, i.c.v.), and abolished by acute bilateral adrenalectomy. On the 
other hand, intravenously administered epibatidine (5 nmol/animal) was largely 
ineffective on the plasma levels of catecholamines, and intravenous pretreatment with 
hexamethonium (1.8 µmol/animal) had no effect on the epibatidine (5 nmol/animal, 
i.c.v.)-induced elevation of both catecholamines. These results suggest that centrally 
administered epibatidine activates the brain nicotinic acethylcholine receptors, thereby
evoking the secretion of noradrenaline and adrenaline from the adrenal medulla by 
brain cyclooxygenase- and prostanoid TP receptor-mediated mechanisms in rats.
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41.  Introduction
Smoking is a leading cause of cardiovascular diseases including high blood 
pressure (Lakier, 1992) and nicotine is one of the components of cigarette smoke. The 
effects of peripherally administered nicotine on the sympatho-adrenomedullary system 
have been clearly shown to evoke the release of noradrenaline and adrenaline from 
sympatho-adrenomedullary system by activation of peripheral nicotinic acethylcholine 
receptors (Watts, 1960; Wang et al., 2000; Yokotani et al., 2001, 2002). Centrally 
administered nicotine also evokes pressor response and elevation of plasma 
catecholamine by activation of the brain nicotinic acethylcholine receptors in rats 
(Kiritsy-Roy et al., 1990; Buccafusco and Yang 1993; Tseng et al., 1993, 1994). 
However, the effect of microinjected nicotine into the brain seems to vary according to 
the injected nuclei. Nicotine administered into the rostral ventrolateral medulla 
increases blood pressure and renal sympathetic nerve activity (Tseng et al., 1993, 
1994), whereas nicotine administration into the nucleus tractus solitarius induces 
hypotension, probably by an enhancement of inhibitory baroreflex (Tseng et al., 1993, 
1994; Ashworth-Preece et al., 1998). Chronic treatment of nicotine is able to intensify 
and accelerate the development of hypertension in spontaneously hypertensive rats 
(Bui et al., 1994; Ferrari and Fior-Chadi, 2007), in which the central dysregulation of 
sympatho-adrenomedullary outflow has been suggested to be involved (Barron and 
Van Loon, 1989; Wyss and Carlson, 2001; Guyenet, 2006). However, the precise 
mechanisms of this alkaloid-induced central modulation of the sympatho-
adrenomedullary outflow are largely undefined.
5We recently reported that centrally administered stress-related neurotransmitters
such as vasopressin, bombesin and histamine elicit adrenal secretion of both 
noradrenaline and adrenaline from noradrenaline- and adrenaline-containing cells in 
the adrenal medulla via the brain thromboxane A2-mediated mechanisms, whereas
centrally administered corticotropin-releasing factor (CRF) and glucagon-like peptide 
1 (GLP-1) elicits adrenaline secretion from adrenal adrenaline-containing cells and 
noradrenaline release from sympathetic nerves via the brain thromboxane A2- and 
prostaglandin E2-mediated mechanisms, respectively, in rats (Okada et al., 2003; 
Yokotani et al., 2005; Shimizu et al., 2006; Arai et al., 2008). In the present study, 
therefore, we examined the mechanisms involved in the centrally administered 
epibatidine (a potent agonist of nicotinic acethylcholine receptors)-induced elevation 
of plasma catecholamines with regard to the brain prostanoids using urethane-
anesthetized rats.
62.  Materials and methods
   
2.1.  Experimental procedures
Male Wistar rats weighing about 350 g were maintained in an air-conditioned 
room at 22-24°C under a constant day-night rhythm for more than 2 weeks and given 
food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. 
Under urethane anesthesia (1.2 g/kg, i.p.), the femoral vein was cannulated for infusion 
of saline (1.2 ml/h), epibatidine or hexamethonium, and the femoral artery was 
cannulated for collecting blood samples. In some experiments, acute bilateral 
adrenalectomy [plus hydrocortisone (5 mg/kg, i.m.)] or sham-operation (plus 200 µl 
saline/animal, i.m.) was done just before these cannulations into the femoral artery and 
vein by an abdominal midline incision (Yokotani et al., 2005; Shimizu et al., 2006; 
Sasaki et al., 2008). After these procedures, the animal was placed in a stereotaxic 
apparatus, as shown in our previous papers (Yokotani et al., 1995; Shimizu et al., 
2004). The skull was drilled for intracerebroventricular administration of test 
substances using a stainless-steel cannula (0.3 mm outer diameter). The stereotaxic 
coordinates of the tip of the cannula were as follows (in mm): AP -0.8, L 1.5, V 4.0 
(AP, anterior from the bregma; L, lateral from the midline; V, below the surface of the 
brain), according to the rat brain atlas (Paxinos and Watson, 1986). Three hours were 
allowed to elapse before the application of epibatidine or blocking reagents.
Epibatidine dissolved in 100% N,N-dimethylformamide (DMF) was slowly 
injected into the right lateral ventricle in a volume of 2.5 µl/animal using a 10-µl 
Hamilton syringe. Each animal received only one dose of epibatidine or vehicle.
7Hexamethonium, water-soluble indomethacin-Na and (+)-S-145 dissolved in sterile 
saline were intracerebroventricularly (i.c.v.) administered in a volume of 5 µl/animal
using a 10-µl Hamilton syringe. When blocking reagents were used, epibatidine was 
i.c.v. administered 30 min after the application of hexamethonium or indomethacin-Na 
and 60 min after the application of (+)-S-145, due to their slightly elevating effects on 
the basal plasma levels of catecholamines. When epibatidine was injected 
intravenously (i.v.), the epibatidine solution (500 µl) dissolved in 0.5% DMF in saline
was slowly injected via a cannula inserted into the femoral vein. Intravenous 
administration of hexamethonium was also carried out via the cannula in a volume of 
500 µl saline/animal. Each animal also received only one dose of blocking reagents or 
vehicle.
All experiments were conducted in compliance with the guiding principles for 
the care and use of laboratory animals approved by Kochi University.
  
2.2.  Measurement of plasma catecholamines
Blood samples (250 µl) were collected through an arterial catheter and were 
preserved on ice during experiments. Plasma was prepared immediately after the final 
sampling. Catecholamines in the plasma were extracted by the method of Anton and 
Sayre (1962) with a slight modification and were assayed electrochemically with high 
performance liquid chromatography (HPLC) (Shimizu et al., 2004). Briefly, after 
centrifugation (1,500 g for 10 min, at 4°C), the plasma (100 µl) was transferred to a 
centrifuge tube containing 30 mg of activated alumina, 2 ml of twice deionized water, 
1 ml of 1.5 M Tris Buffer (pH 8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-
8dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the 
alumina was washed three times with 4 ml of ice-cold twice deionized water. Then, 
catecholamines adsorbed onto the alumina were eluted with 300 µl of 4% acetic acid 
containing 0.1 mM disodium EDTA. The extraction efficiency of catecholamines was 
about 83.8±1.6% (n=4). A pump (EP-300: Eicom, Kyoto, Japan), a sample injector 
(Model-231XL; Gilson, Villiers-le-Bel, France) and an electrochemical detector (ECD-
300: Eicom) equipped with a graphite electrode were used with HPLC. Analytical 
conditions were as follows: detector, +450 mV potential against an Ag/AgCl reference 
electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M 
NaH2PO4-Na2HPO4 buffer (pH 6.0) containing 50 mg/l disodium EDTA, 0.75 g/l 
sodium 1-octanesulfonate and 15% methanol at a flow rate of 0.18 ml/min; injection 
volume, 40 µl. The amount of catecholamines in each sample was calculated using the 
peak height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, 
coefficients of variation for intra- and inter-assay were 3.0 and 3.7%, respectively, and 
0.5 pg of noradrenaline and adrenaline was accurately determined.
2.3.  Treatment of data and statistics 
All values are expressed as the means±S.E.M. of the net changes above the 
respective basal values. The data were analyzed by repeated-measure analysis of 
variance (ANOVA), followed by post-hoc analysis with the Bonferroni method for 
comparing a control to all other means (Figs. 1A, 2A, 3 and 4). When only two means 
9were compared, an unpaired Student’s t-test or Welch’s t-test was used (Figs. 1B, 2B 
and 5). P values less than 0.05 were taken to indicate statistical significance.
2.4.  Compounds
The following drugs were used: (±)-epibatidine dihydrochloride hydrate 
(epibatidine), hexamethonium chloride and hydrocortisone (Sigma Aldrich Fine 
Chemicals, St. Louis, MO, U.S.A.); water-soluble indomethacin sodium trihydrate (a 
kind gift from Merck Rahway, NJ, U.S.A.); (+)-S-145 [(+)-(1R,2S,3S,4S)-(5Z)-7-(3-
phenylsulphonyl-aminobicyclo[2.2.1]hept-2-yl)hept-5-enoic acid] (a kind gift from 
Shionogi Pharmaceutical Co. Ltd., Osaka, Japan). All other reagents were of the 
highest grade available (Nacalai Tesque, Kyoto, Japan).
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3.  Results
3.1.  Effect of centrally administered epibatidine on plasma levels of catecholamines 
I.c.v. administered vehicle (2.5 µl DMF/animal) had no effect on the basal 
plasma levels of either noradrenaline or adrenaline, respectively (Fig. 1A). Epibatidine
[1 nmol (0.3 µg)/animal, i.c.v.] had little effect on the plasma levels of noradrenaline 
and adrenaline, but this chloroalkaloid [5 and 10 nmol (1.4 and 2.8 µg)/animal, i.c.v.] 
significantly elevated plasma levels of noradrenaline and adrenaline; maximal 
noradrenaline responses were obtained by a dose of 10 nmol/animal (i.c.v.) and 
maximal adrenaline responses were obtained by a dose of 5 nmol/animal (i.c.v.), 
respectively (Fig. 1A). These responses reached a maximum 5 min after the 
administration of epibatidine and then gradually declined toward their basal levels. 
Intravenous administration of vehicle (500 µl of 0.5% DMF in saline) had no 
effect on the basal plasma levels of either noradrenaline or adrenaline (Fig. 1B). 
Epibatidine (5 nmol/animal, i.v.) largely unaffected the plasma levels of both
catecholamines (Fig. 1B).
3.2.  Effect of hexamethonium (an antagonist of nicotinic acethylcholine receptors) on 
the centrally administered epibatidine-induced elevation of plasma catecholamines 
Treatments with vehicle-1 (5 µl saline/animal, i.c.v.)/hexamethonium [1.8 µmol
(500 µg)/animal, i.c.v.] and vehicle-2 (2.5 µl DMF/animal, i.c.v.) had no effect on the 
basal plasma levels of noradrenaline and adrenaline, respectively (Fig. 2A). 
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Epibatidine (5 nmol/animal, i.c.v.)-induced elevation of noradrenaline was 
significantly reduced by hexamethonium (1.8 µmol/animal, i.c.v.), while the reagent-
induced elevation of plasma adrenaline was dose-dependently reduced by 
hexamethonium [0.9 and 1.8 µmol (250 and 500 µg)/animal, i.c.v.] (Fig. 2A). 
Treatments with vehicle-1 (500 µl saline/animal, i.v.)/hexamethonium (1.8 
µmol/animal, i.v.) and vehicle-2 (2.5 µl DMF/animal, i.c.v.) had no effect on the basal 
plasma levels of noradrenaline and adrenaline, respectively (Fig. 2B). Pretreatment 
with hexamethonium (1.8 µmol/animal, i.v.) had little effect on the epibatidine (5 
nmol/animal, i.c.v.)-induced elevation of both catecholamines (Fig. 2B).
3.3.  Effect of indomethacin (an inhibitor of cyclooxygenase) on the centrally 
administered epibatidine-induced elevation of plasma catecholamines 
Treatments with vehicle-1 (5 µl saline/animal, i.c.v.)/indomethacin [1.2 µmol
(500 µg)/animal, i.c.v.] and vehicle-2 (2.5 µl DMF/animal, i.c.v.) had no effect on the 
basal plasma levels of noradrenaline and adrenaline, respectively (Fig. 3). 
Epibatidine (5 nmol/animal, i.c.v.)-induced elevation of noradrenaline and 
adrenaline was dose-dependently reduced by indomethacin [0.6 and 1.2 µmol (250 and 
500 µg)/animal, i.c.v.] (Fig. 3). 
3.4.  Effect of (+)-S-145 (an antagonist of prostanoid TP receptors) on the centrally 
administered epibatidine-induced elevation of plasma catecholamines 
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Treatments with vehicle-1 (5 µl saline/animal, i.c.v.)/(+)-S-145 [1.3 µmol (500
µg)/animal, i.c.v.] and vehicle-2 (2.5 µl DMF/animal, i.c.v.) had no effect on the basal 
plasma levels of noradrenaline and adrenaline, respectively (Fig. 4). 
Epibatidine (5 nmol/animal, i.c.v.)-induced elevation of both catecholamines was
significantly reduced by (+)-S-145 [0.6 and 1.3 µmol (250 and 500 µg)/animal, i.c.v.] 
(Fig. 4).
3.5.  Effect of bilateral adrenalectomy on the centrally administered epibatidine-
induced elevation of plasma catecholamines 
The basal plasma levels of noradrenaline were not influenced by bilateral 
adrenalectomy, while the basal plasma levels of adrenaline were effectively, but not 
significantly, reduced by this procedure (Fig. 5).
In sham-operated rats, epibatidine (5 nmol/animal, i.c.v.) effectively elevated 
plasma levels of noradrenaline and adrenaline (Fig. 5). The reagent-induced elevation 
of both catecholamines was abolished by bilateral adrenalectomy (Fig. 5). 
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4.  Discussion
In the preliminary experiment, centrally administered nicotine (250 and 500 
nmol/animal, i.c.v.) dose-dependently evoked a rapid increase of plasma levels of 
adrenaline and noradrenaline within 3 min after the administration of this alkaloid, and 
quickly returned to the preadministered basal levels, as shown by Kiritsy-Roy et al. 
(1990). Due to the rapid response of nicotine, we used epibatidine in the present 
experiments to clarify the mechanisms involved in the brain nicotinic acetylcholine 
receptor-induced elevation of plasma catecholamines in rats. Epibatidine obtained 
from the skin of the Ecuadoran frog Epipedobates tricolar (Daly et al., 1978) is a 
highly potent nicotinic acethylcholine receptor agonist having broad spectrum activity 
on the nicotinic acethylcholine receptors (Qian et al., 1993; Badio and Daly, 1994; 
Lembeck, 1999). In the present experiment, centrally administered epibatidine (5 and 
10 nmol/animal) dose-dependently elevated plasma levels of noradrenaline and 
adrenaline in rats. A possibility has arisen that the centrally administered 
chloroalkaloid leaks out into the systemic circulation, thereby peripherally activating 
nicotinic receptors located on the sympathetic nerves and adrenal medulla. However, 
peripherally administered epibatidine (5 nmol/animal) had little effect on the plasma 
catecholamines. Furthermore, centrally administered epibatidine (5 nmol/animal)-
induced responses were effectively attenuated by central pretreatment with 
hexamethonium (an antagonist of nicotinic acethylcholine receptors), but not 
influenced by peripheral pretreatment with the same dose of this reagent. These results 
suggest that centrally administered epibatidine acts on the nicotinic acethylcholine 
14
receptors in the brain, thereby elevating plasma levels of noradrenaline and adrenaline 
in rats.
Prostanoids (prostaglandins and thromboxane A2) generated by several enzymes, 
including cyclooxygenase, have been demonstrated to act as a neurotransmitter and/or 
neuromodulator in the brain’s actions such as cardiovascular function (Wood et al., 
1993; Zhang et al., 2003) and regulation of hormone secretion (Bernardini et al., 1989; 
Reimsnider and Wood, 2006). Previously, we reported that central pretreatment with 
indomethacin or ketoprofen (inhibitors of cyclooxygenase) attenuated the centrally 
administered CRF-, vasopressin-, histamine-, GLP-1- and bombesin-induced elevation 
of plasma noradrenaline and adrenaline (Okada et al., 2003; Shimizu et al., 2006; Arai 
et al., 2008; Lu et al., 2008), suggesting the involvement of the brain prostanoids in 
these substances-induced elevation of plasma catecholamines in rats. In the present 
study, central pretreatment with indomethacin effectively attenuated the elevation of 
plasma noradrenaline and adrenaline induced by centrally administered epibatidine. 
The result also suggests the involvement of brain prostanoids in the epibatidine-
induced elevation of plasma catecholamines in rats.
Plasma adrenaline is mainly secreted from adrenaline-containing cells in the 
adrenal medulla, whereas plasma noradrenaline reflects not only the release from 
sympathetic nerves but also the secretion from noradrenaline-containing cells in the 
adrenal medulla (Edwards et al., 1996; Suzuki and Kachi, 1996; Vollmer et al., 2000; 
Yamaguchi-Shima, et al., 2007). We previously reported that centrally administered 
prostaglandin E2 (but not prostaglandin D2, I2 and F2alpha) elevates plasma 
noradrenaline from sympathetic nerves by activation of the brain prostanoid EP3
receptors in rats (Yokotani et al., 1995, 2005; Murakami et al. 2002) and also that 
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microinjection of thromboxane A2 mimetic into the hypothalamic paraventricular 
nucleus predominantly elevates plasma adrenaline by activation of the brain prostanoid 
TP receptors in rats (Murakami et al., 2002). Furthermore, the brain prostanoid TP
receptors are involved in the centrally administered vasopressin-, bombesin- and 
histamine-induced secretion of both noradrenaline and adrenaline from noradrenaline-
and adrenaline-containing cells in the adrenal medulla and in the centrally
administered CRF- and GLP-1-induced secretion of adrenaline from adrenaline-
containing cells in the adrenal medulla in rats (Okada et al., 2003; Yokotani et al., 
2005; Shimizu et al., 2006; Arai et al., 2008). The activation of brain TP receptors has 
been shown to elevate blood pressure and plasma catecholamines in hemorrhaged
hypotensive rats (Yalcin and Savci, 2004). In the present study, central pretreatment 
with (+)-S-145 [an antagonist of prostanoid TP receptors (Hanasaki and Arita 1988; 
Mihara et al. 1989)] effectively attenuated the elevation of plasma noradrenaline and 
adrenaline induced by centrally administered epibatidine. The result suggests a 
possibility that centrally administered epibatidine elicits the secretion of both 
noradrenaline and adrenaline from the adrenal medulla by brain prostanoid TP 
receptor-mediated mechanisms in rats.
To further explore the source of noradrenaline and adrenaline elicited by 
centrally administered epibatidine, we examined the effect of acute bilateral 
adrenalectomy on the epibatidine-induced elevation of plasma catecholamines.
Previously, we reported that bilateral adrenalectomy abolished the elevation of plasma 
noradrenaline and adrenaline induced by centrally administered vasopressin, bombesin
and histamine (Okada et al., 2003; Yokotani et al., 2005; Shimizu et al., 2006). In the 
present study, bilateral adrenalectomy abolished the centrally administered epibatidine-
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induced elevation of both plasma noradrenaline and adrenaline. The result suggests 
that centrally administered epibatidine elicits the secretion of both noradrenaline and 
adrenaline from the adrenal medulla in rats.
In the central nervous system, nicotinic acethylcholine receptors are
preferentially located at presynaptic terminals, thereby regulating the release of many 
neurotransmitters (Wonnacott, 1997; Vizi and Lendvai, 1999; Gotti and Clementi, 
2004; Sher et al., 2004) such as glutamate in the rat prefrontal cortex, striatal 
synaptosomes and nucleus tractus solitarius (Marchi et al., 2002; Zhao et al., 2007; 
Dickinson et al., 2008). Glutamate excites the hypothalamic paraventricular nucleus 
(Boudaba et al., 1997; Li et al., 2004), which has been considered to be the control 
center of the sympatho-adrenomedullary outflow (Swanson and Sawchenko, 1980; 
Jansen et al., 1995; Kenny et al., 2003). Previously, we reported that N-methyl-D-
aspartate applied into this nucleus using dialysis probe elicited concomitant overflow 
of hypothalamic thromboxane B2 (a stable metabolite of thromboxane A2) with the 
elevation of plasma noradrenaline and adrenaline in rats (Okada et al., 2000). These 
lines of evidence suggest a possibility that activation of the hypothalamic nicotinic 
acethylcholine receptors evokes the secretion of noradrenaline and adrenaline from 
adrenal medulla by glutamate- and thromboxane A2-mediated mechanisms in rats.
Further experiments are required to explore the mechanisms for central nicotinic 
acethylcholine receptors to activate the central adrenomedullary outflow in rats.  
In summary, we demonstrated here that centrally administered epibatidine 
activates central nicotinic acethylcholine receptors, thereby evoking the secretion of 
noradrenaline and adrenaline from the adrenal medulla by brain cyclooxygenase- and 
prostanoid TP receptor-mediated mechanisms in rats.
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Legends to figures
Fig. 1. Effect of centrally and peripherally administered epibatidine on the plasma 
levels of catecholamines. ∆Noradrenaline and ∆Adrenaline: increments of 
noradrenaline and adrenaline above the basal level. Each point represents the 
mean±S.E.M. (A) Arrow indicates the administration of vehicle (DMF 2.5 µl/animal, 
i.c.v.) or epibatidine (1, 5 and 10 nmol/animal, i.c.v.). *Significantly different from the 
vehicle-treated group with the Bonferroni method [noradrenaline; at 5 min, 
F(3,14)=20.78, P<0.017; at 10 min, F(3,14)=13.07, P<0.017: adrenaline; at 5 min, 
F(3,14)=6.30, P<0.017; at 10 min, F(3,14)=7.75, P<0.017; at 30 min, F(3,14)=4.53, 
P<0.017; at 60 min, F(3,13)=5.85, P<0.017]. The actual values for noradrenaline and 
adrenaline at 0 min were 186±22 and 211±35 pg/ml (n=18), respectively. (B) Arrow 
indicates the administration of vehicle (0.5% DMF/saline 500 µl/animal, i.v.) or 
epibatidine (5 nmol/animal, i.v.). *Significantly different from the vehicle-treated 
group with Welch’s t-test [adrenaline; at 30 min, F(3,5)=32.3, P<0.05]. The actual 
values for noradrenaline and adrenaline at 0 min were 146±9 and 176±48 pg/ml (n=10), 
respectively.
Fig. 2. Effect of hexamethonium (an antagonist of nicotinic acethylcholine receptors) 
on the centrally administered epibatidine-induced elevation of plasma catecholamines.
Arrows indicate the administrations of hexamethonium/vehicle-1 and 
epibatidine/vehicle-2. Other conditions were the same as those of Fig. 1. (A)
Hexamethonium (0.9 and 1.8 µmol/animal) or vehicle-1 (5 µl saline/animal) was i.c.v. 
administered 30 min before the administration of epibatidine (5 nmol/animal, i.c.v.) or 
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vehicle-2 (2.5 µl DMF/animal, i.c.v.). *Significantly different from vehicle-1- and 
epibatidine-treated group with the Bonferroni method [noradrenaline; at 5 min, 
F(2,13)=8.07, P<0.025; at 10 min, F(2,13)=6.05, P<0.025: adrenaline; at 5 min, 
F(2,13)=33.87, P<0.025; at 10 min, F(2,13)=49.78, P<0.025; at 30 min, 
F(2,13)=11.34, P<0.025; at 60 min, F(2,13)=10.70, P<0.025]. The actual values for 
noradrenaline and adrenaline at 0 min were 299±62 and 304±107 pg/ml in the vehicle-
1-pretreated group (n=9); 419±88 and 606±134 pg/ml in the hexamethonium (0.9 
µmol/animal)-pretreated group (n=6); 223±22 and 316±64 pg/ml in the 
hexamethonium (1.8 µmol/animal)-pretreated group (n=9), respectively. (B) 
Hexamethonium (1.8 µmol/animal) or vehicle-1 (500 µl saline/animal) was i.v. 
administered 30 min before the administration of epibatidine (5 nmol/animal, i.c.v.) or 
vehicle-2 (2.5 µl DMF/animal, i.c.v.). The actual values for noradrenaline and 
adrenaline at 0 min were 376±83 and 290±62 pg/ml in the vehicle-1-pretreated group 
(n=10); 164±15 and 328±40 pg/ml in the hexamethonium (1.8 µmol/animal)-
pretreated group (n=10), respectively. 
Fig. 3. Effect of indomethacin (an inhibitor of cyclooxygenase) on the centrally 
administered epibatidine-induced elevation of plasma catecholamines. Arrows indicate 
the administration of indomethacin/vehicle-1 and epibatidine/vehicle-2. Indomethacin
(0.6 and 1.2 µmol/animal) or vehicle-1 (5 µl saline/animal) was i.c.v. administered 30 
min before the administration of epibatidine (5 nmol/animal, i.c.v.) or vehicle-2 (2.5 µl 
DMF/animal, i.c.v.). Other conditions were the same as those of Figs. 1 and 2. 
*Significantly different from vehicle-1- and epibatidine-treated group with the 
Bonferroni method [noradrenaline; at 5 min, F(2,11)=7.76, P<0.025; at 10 min, 
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F(2,11)=5.17, P<0.025: adrenaline; at 5 min, F(2,11)=10.17, P<0.025; at 10 min, 
F(2,11)=3.94, P<0.025]. Vehicle-1-treated groups were the same as those of Fig. 2A. 
The actual values for noradrenaline and adrenaline at 0 min were 193±69 and 418±63 
pg/ml in the indomethacin (0.6 µmol/animal)-pretreated group (n=4); 208±32 and 
299±59 pg/ml in the indomethacin (1.2 µmol/animal)-pretreated group (n=9), 
respectively.  
Fig. 4. Effect of (+)-S-145 (an antagonist of prostanoid TP receptors) on the centrally 
administered epibatidine-induced elevation of plasma catecholamines. Arrows indicate 
the administration of (+)-S-145/vehicle-1 and epibatidine/vehicle-2. (+)-S-145 (0.6 and 
1.3 µmol/animal) or vehicle-1 (5 µl saline/animal) was i.c.v. administered 60 min 
before the administration of epibatidine (5 nmol/animal, i.c.v.) or vehicle-2 (2.5 µl 
DMF/animal, i.c.v.). Other conditions were the same as those in Figs. 1-3.  
*Significantly different from the vehicle-1- and epibatidine-treated group with the 
Bonferroni method [noradrenaline; at 5 min, F(2,12)=9.95, P<0.025; at 10 min, 
F(2,12)=5.28, P<0.025: adrenaline; at 5 min, F(2,12)=10.54, P<0.025; at 10 min, 
F(2,12)=4.69, P<0.025]. The actual values for noradrenaline and adrenaline at 0 min 
were 276±56 and 179±49 pg/ml in the vehicle-1-pretreated group (n=10); 246±45 and 
145±27 pg/ml in the (+)-S-145 (0.6 µmol/animal)-pretreated group (n=5); 303±39 and 
161±24 pg/ml in the (+)-S-145 (1.3 µmol/animal)-pretreated group (n=9), respectively.  
Fig. 5. Effect of acute bilateral adrenalectomy on the centrally administered
epibatidine-induced elevation of plasma catecholamines. Acute bilateral adrenalectomy 
[plus hydrocortisone (5 mg/kg/animal, i.m.)] or sham-operation (plus 200 µl
30
saline/animal, i.m.) was done 3 h before the application of epibatidine (5 nmol/animal, 
i.c.v.). Arrow indicates the administration of epibatidine. Other conditions were the 
same as those in Figs. 1-4. *Significantly different from the sham-operated group with 
an unpaired Student’s t-test or Welch’s t-test [noradrenaline; at 5 min, F(4,4)=6.51, 
P<0.05; at 10 min, F(4,4)=5.92, P<0.05; at 30 min, F(4,4)=1.36, P<0.05; at 60 min, 
F(4,4)=2.13, P<0.05: adrenaline; at 5 min, F(4,4)=50.97, P<0.05; at 10 min, 
F(4,4)=2.88, P<0.05]. The actual values for noradrenaline and adrenaline at 0 min 
were 172±21 and 129±36 pg/ml in sham-operated group (n=5) and 191±50 and 51±28 
pg/ml in bilateral adrenalectomized group (n=5), respectively.
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